NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Explore this paper's citation graph
Summary
The findings support the rational inhibition of members of the NF-κB pathway as a promising therapeutic option for patients who progress after treatment with novel mutant-selective EGFR-TKIs.
- Type
- article
- Published
- 2015-04-29
- Cited by
- 37
- References
- 61
- Access
- Open access
- OpenAlex
- https://openalex.org/W1685156615
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:17699708
Keywords
T790M, Gefitinib, Afatinib, Erlotinib, Lung cancer
References
- KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
- Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
- Abstract 3745: The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses
- Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase
- Abstract 4832: Novel EGFR mutations that cause drug resistance to irreversible pyrimidine but not quinazoline based EGFR inhibitors
- Interstitial lung disease associated with drug therapy
- Non-canonical NF-κB signaling pathway
- Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
- Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.
- The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Dermatologic side effects associated with gefitinib therapy: clinical experience and management.
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
- EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells
- Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis.
- Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Cited by
- Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
- The CRISPR/Cas9 system targeting EGFR exon 17 abrogates NF-κB activation via epigenetic modulation of UBXN1 in EGFRwt/vIII glioma cells.
- Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
- Resistance Mechanisms to AZD9291 and Rociletinib—Letter
- Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI
- Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
- Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
- A novel nucleolin aptamer-celastrol conjugate (NACC) with super antitumor activity on advanced pancreatic cancer
- Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
- Inhibition of NF‐κB improves sensitivity to irradiation and EGFR‐TKIs and decreases irradiation‐induced lung toxicity
- Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling
- Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach
- CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
- From ‘Targeted Therapy’ to Targeted Therapy*
- Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?
- Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway
- Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations
- CDRgator: An Integrative Navigator of Cancer Drug Resistance Gene Signatures
- Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells
- The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer
Related papers
- Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
- Re-use of erlotinib in a patient using osimertinib after erlotinib, case report
- Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
- EGFR mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib
- The effect of erlotinib on EGFR and downstream signaling in oral cavity squamous cell carcinoma
- Abstract 5505: MyD88-dependent signaling decreases the anti-tumor efficacy of epidermal growth factor receptor inhibition in head and neck cancer cells
- Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
- MyD88-dependent signaling decreases the anti-tumor efficacy of epidermal growth factor receptor inhibition in head and neck cancer cells
- Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer